The Korean Academy of Asthma Allergy and Clinical Immunology guidelines for allergen immunotherapy
- Author:
Hwa Young LEE
1
;
Sung-Yoon KANG
;
Kyunghoon KIM
;
Ju Hee KIM
;
Gwanghui RYU
;
Jin-Young MIN
;
Kyung Hee PARK
;
So-Young PARK
;
Myongsoon SUNG
;
Youngsoo LEE
;
Eun-Ae YANG
;
Hye Mi JEE
;
Eun Kyo HA
;
Yoo Seob SHIN
;
Sang Min LEE
;
Eun Hee CHUNG
;
Sun Hee CHOI
;
Young-Il KOH
;
Seon Tae KIM
;
Dong-Ho NAHM
;
Jung Won PARK
;
Jung Yeon SHIM
;
Young Min AN
;
Doo Hee HAN
;
Man Yong HAN
;
Yong Won LEE
;
Jeong-Hee CHOI
;
Author Information
- Publication Type:REVIEW
- From:Allergy, Asthma & Respiratory Disease 2024;12(3):102-124
- CountryRepublic of Korea
- Language:English
- Abstract: Allergen immunotherapy (AIT) is a causative treatment of allergic diseases in which allergen extracts are regularly administered in a gradually escalated doses, leading to immune tolerance and consequent alleviation of allergic diseases. The need for uniform practice guidelines in AIT is continuously growing as the number of potential candidates for AIT increases and new therapeutic approaches are tried. This updated version of the Korean Academy of Asthma Allergy and Clinical Immunology recommendations for AIT, published in 2010, proposes an expert opinion by specialists in allergy, pediatrics, and otorhinolaryngology. This guideline deals with the basic knowledge of AIT, including mechanisms, clinical efficacy, allergen standardization, important allergens in Korea, and special consideration in pediatrics. The article also covers the methodological aspects of AIT, including patient selection, allergen selection, schedule and doses, follow-up care, efficacy measurements, and management of adverse reactions. Although this guideline suggests the optimal dosing schedule, an individualized approach and modifications are recommended considering the situation for each patient and clinic.
